|
12 Companies |
|
24 Products |
|
24 Products |
|
30 Mechanisms of Action |
|
0 Trials |
|
37 News |
|
- | vatalanib (PTK787) / Novartis, Bayer
Trial completion, Trial primary completion date, Combination therapy, Metastases: Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors (clinicaltrials.gov) - Jan 17, 2018
P1, N=96, Completed, Sponsor: Mayo Clinic
Active, not recruiting --> Completed | Trial primary completion date: Dec 2017 --> Sep 2009
- | Avastin (bevacizumab) / Roche, Torisel (temsirolimus) / Pfizer
Trial completion, Trial primary completion date: Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer (clinicaltrials.gov) - Jul 11, 2017
P2, N=252, Completed, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed | Trial primary completion date: Dec 2017 --> Sep 2009 Active, not recruiting --> Completed | Trial primary completion date: Sep 2017 --> Mar 2017
- | vatalanib (PTK787) / Novartis, Bayer
Trial primary completion date, Combination therapy, Metastases: Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors (clinicaltrials.gov) - Mar 22, 2017
P1, N=96, Active, not recruiting, Sponsor: Mayo Clinic
Active, not recruiting --> Completed | Trial primary completion date: Sep 2017 --> Mar 2017 Trial primary completion date: Dec 2016 --> Dec 2017
- | Avastin (bevacizumab) / Roche, Torisel (temsirolimus) / Pfizer
Trial primary completion date: Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer (clinicaltrials.gov) - Mar 10, 2017
P2, N=299, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Dec 2016 --> Dec 2017 Trial primary completion date: Jun 2016 --> Sep 2017
- 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
Trial completion, Surgery, Metastases: Combination Chemotherapy as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors of the Duodenum or Pancreas That Cannot Be Removed By Surgery (clinicaltrials.gov) - May 31, 2016
P2, N=20, Completed, Sponsor: Federation Francophone de Cancerologie Digestive
Trial primary completion date: Jun 2016 --> Sep 2017 Active, not recruiting --> Completed
- cixutumumab (IMC A12) / Eli Lilly
Trial completion, Trial primary completion date, Metastases: Cixutumumab, Everolimus, and Octreotide Acetate in Treating Patients With Advanced Low to Intermediate Grade Neuroendocrine Carcinoma (clinicaltrials.gov) - May 13, 2016
P1, N=27, Completed, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Active, not recruiting --> Completed | Trial primary completion date: May 2013 --> Jul 2014
- vatalanib (PTK787) / Novartis, Bayer
Trial primary completion date, Combination therapy, Metastases: Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors (clinicaltrials.gov) - Mar 16, 2016
P1, N=96, Active, not recruiting, Sponsor: Mayo Clinic
Active, not recruiting --> Completed | Trial primary completion date: May 2013 --> Jul 2014 Trial primary completion date: Dec 2015 --> Dec 2016
- Avastin (bevacizumab) / Roche, Torisel (temsirolimus) / Pfizer
Trial primary completion date: Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer (clinicaltrials.gov) - Feb 23, 2016
P2, N=299, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Dec 2015 --> Dec 2016 Trial primary completion date: Feb 2016 --> Jun 2016
- everolimus / Generic mfg.
Enrollment change, Trial termination, Trial primary completion date: Pharmacokinetically Guided Everolimus in Patients With Breast Cancer, Pancreatic Neuroendocrine Tumors, or Kidney Cancer (clinicaltrials.gov) - Jan 15, 2016
P2, N=2, Terminated, Sponsor: Emory University
Trial primary completion date: Feb 2016 --> Jun 2016 N=26 --> 2 | Recruiting --> Terminated | Trial primary completion date: Oct 2016 --> Dec 2015; Slow accrual
- cixutumumab (IMC A12) / Eli Lilly
Enrollment change, Metastases: Cixutumumab, Everolimus, and Octreotide Acetate in Treating Patients With Advanced Low to Intermediate Grade Neuroendocrine Carcinoma (clinicaltrials.gov) - Dec 9, 2015
P1, N=27, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
N=26 --> 2 | Recruiting --> Terminated | Trial primary completion date: Oct 2016 --> Dec 2015; Slow accrual N=19 --> 27
- dovitinib (TKI258) / Novartis, Oncoheroes
Enrollment change, Trial withdrawal, Trial primary completion date: Dovitinib Lactate in Treating Patients With Pancreatic Neuroendocrine Tumors (clinicaltrials.gov) - Aug 6, 2015
P2, N=0, Withdrawn, Sponsor: Academic and Community Cancer Research United
N=19 --> 27 N=63 --> 0 | Active, not recruiting --> Withdrawn | Trial primary completion date: Dec 2016 --> May 2015
- Avastin (bevacizumab) / Roche, Torisel (temsirolimus) / Pfizer
Trial primary completion date: Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer (clinicaltrials.gov) - Jul 17, 2015
P2, N=299, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
N=63 --> 0 | Active, not recruiting --> Withdrawn | Trial primary completion date: Dec 2016 --> May 2015 Trial primary completion date: Aug 2015 --> Dec 2015
- | motesanib (AMG 706) / Takeda
Trial completion, Trial primary completion date: AMG 706 and Octreotide in Treating Patients With Low-Grade Neuroendocrine Tumors (clinicaltrials.gov) - Jun 4, 2015
P2, N=46, Completed, Sponsor: Eastern Cooperative Oncology Group
Trial primary completion date: Aug 2015 --> Dec 2015 Active, not recruiting --> Completed | Trial primary completion date: Nov 2012 --> Oct 2014
- || vatalanib (PTK787) / Novartis, Bayer
Trial primary completion date, Combination therapy, Metastases: Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors (clinicaltrials.gov) - Apr 19, 2015
P1, N=96, Active, not recruiting, Sponsor: Mayo Clinic
Active, not recruiting --> Completed | Trial primary completion date: Nov 2012 --> Oct 2014 Trial primary completion date: Dec 2014 --> Dec 2015
- dovitinib (TKI258) / Novartis, Oncoheroes
Enrollment closed: Dovitinib Lactate in Treating Patients With Pancreatic Neuroendocrine Tumors (clinicaltrials.gov) - Mar 12, 2015
P2, N=63, Active, not recruiting, Sponsor: Academic and Community Cancer Research United
Trial primary completion date: Dec 2014 --> Dec 2015 Recruiting --> Active, not recruiting
- Avastin (bevacizumab) / Roche, Torisel (temsirolimus) / Pfizer
Trial primary completion date: Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer (clinicaltrials.gov) - Feb 10, 2015
P2, N=299, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting Trial primary completion date: Mar 2015 --> Aug 2015
- Avastin (bevacizumab) / Roche, Torisel (temsirolimus) / Pfizer
Enrollment closed: Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer (clinicaltrials.gov) - Jan 2, 2015
P2, N=299, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Mar 2015 --> Aug 2015 Recruiting --> Active, not recruiting
- dovitinib (TKI258) / Novartis, Oncoheroes
Enrollment open, Trial initiation date: Dovitinib Lactate in Treating Patients With Pancreatic Neuroendocrine Tumors (clinicaltrials.gov) - Nov 17, 2014
P2, N=63, Recruiting, Sponsor: Academic and Community Cancer Research United
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting | Initiation date: Apr 2014 --> Oct 2014
- sorafenib / Generic mfg.
Trial completion, Metastases: Sorafenib Tosylate in Treating Patients With Progressive Metastatic Neuroendocrine Tumors (clinicaltrials.gov) - Nov 17, 2014
P2, N=93, Completed, Sponsor: National Cancer Institute (NCI)
Not yet recruiting --> Recruiting | Initiation date: Apr 2014 --> Oct 2014 Active, not recruiting --> Completed
- | everolimus / Generic mfg.
Enrollment open: Pharmacokinetically Guided Everolimus in Patients With Breast Cancer, Pancreatic Neuroendocrine Tumors, or Kidney Cancer (clinicaltrials.gov) - Nov 5, 2014
P2, N=26, Recruiting, Sponsor: Emory University
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- temozolomide / Generic mfg., capecitabine / Generic mfg.
Trial completion, Metastases: Capecitabine and Temozolomide for Neuroendocrine Cancers (clinicaltrials.gov) - Nov 4, 2014
P2, N=38, Completed, Sponsor: Columbia University
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- | everolimus / Generic mfg.
New P2 trial: Pharmacokinetically Guided Everolimus in Patients With Breast Cancer, Pancreatic Neuroendocrine Tumors, or Kidney Cancer (clinicaltrials.gov) - Oct 24, 2014
P2, N=26, Not yet recruiting, Sponsor: Emory University
- Enrollment closed: Doxorubicin Beads in Treating Patients With Unresectable Liver Metastases From Neuroendocrine Tumors (clinicaltrials.gov) - Oct 2, 2014
P=N/A, N=30, Active, not recruiting, Sponsor: Sidney Kimmel Comprehensive Cancer Center
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- Avastin (bevacizumab) / Roche, Torisel (temsirolimus) / Pfizer
Trial suspension: Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer (clinicaltrials.gov) - Jul 16, 2014
P2, N=299, Suspended, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting Recruiting --> Suspended
- Trial termination: Indium In 111 Pentetreotide in Treating Patients With Refractory Cancer (clinicaltrials.gov) - Jul 2, 2014
P1, N=35, Terminated, Sponsor: Yale University
Recruiting --> Suspended Active, not recruiting --> Terminated
- || vatalanib (PTK787) / Novartis, Bayer
Trial primary completion date, Combination therapy, Metastases: Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors (clinicaltrials.gov) - Jun 19, 2014
P1, N=96, Active, not recruiting, Sponsor: Mayo Clinic
Active, not recruiting --> Terminated Trial primary completion date: Sep 2014 --> Dec 2014
- | dovitinib (TKI258) / Novartis, Oncoheroes
New P2 trial: Dovitinib Lactate in Treating Patients With Pancreatic Neuroendocrine Tumors (clinicaltrials.gov) - Apr 7, 2014
P2, N=63, Not yet recruiting, Sponsor: Academic and Community Cancer Research United
- Avastin (bevacizumab) / Roche, Torisel (temsirolimus) / Pfizer
Enrollment open: Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer (clinicaltrials.gov) - Apr 3, 2014
P2, N=299, Recruiting, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Sep 2014 --> Dec 2014 Suspended --> Recruiting
- cixutumumab (IMC A12) / Eli Lilly
Enrollment change, Metastases: Cixutumumab, Everolimus, and Octreotide Acetate in Treating Patients With Advanced Low to Intermediate Grade Neuroendocrine Carcinoma (clinicaltrials.gov) - Mar 19, 2014
P1, N=19, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Suspended --> Recruiting N=48 --> 19
- | gefitinib / Generic mfg.
Trial completion, Metastases: Gefitinib in Treating Patients With Progressive Metastatic Neuroendocrine Tumors (clinicaltrials.gov) - Feb 22, 2014
P2, N=90, Completed, Sponsor: National Cancer Institute (NCI)
N=48 --> 19 Active, not recruiting --> Completed
- | thalidomide / Generic mfg.
Trial completion, Metastases: Thalidomide in Treating Patients With Metastatic Neuroendocrine Tumors (clinicaltrials.gov) - Feb 22, 2014
P2, N=0, Completed, Sponsor: Memorial Sloan-Kettering Cancer Center
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Herceptin (trastuzumab) / Roche
Trial completion: Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu (clinicaltrials.gov) - Feb 19, 2014
P1, N=15, Completed, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Active, not recruiting --> Completed
- temozolomide / Generic mfg., capecitabine / Generic mfg.
Enrollment closed, Metastases: Capecitabine and Temozolomide for Neuroendocrine Cancers (clinicaltrials.gov) - Jan 21, 2014
P2, N=38, Active, not recruiting, Sponsor: Columbia University
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- ||| melphalan / Generic mfg.
Enrollment change, Metastases: Hepatic Arterial Infusion of Melphalan With Hepatic Perfusion in Treating Patients With Unresectable Liver Cancer (clinicaltrials.gov) - Oct 21, 2013
P2, N=56, Completed, Sponsor: Delcath Systems Inc.
Recruiting --> Active, not recruiting N=105 --> 56
- |||| melphalan / Generic mfg.
Trial completion, Metastases: Hepatic Arterial Infusion of Melphalan With Hepatic Perfusion in Treating Patients With Unresectable Liver Cancer (clinicaltrials.gov) - Oct 21, 2013
P2, N=56, Completed, Sponsor: Delcath Systems Inc.
N=105 --> 56 Active, not recruiting --> Completed
- Zanosar (streptozocin) / Teva
Trial completion, Metastases: Capecitabine and Streptozocin With or Without Cisplatin in Treating Patients With Unresectable or Metastatic Neuroendocrine Tumors (clinicaltrials.gov) - Aug 5, 2013
P2, N=84, Completed, Sponsor: Cambridge University Hospitals NHS Foundation Trust
Active, not recruiting --> Completed Recruiting --> Completed
- temozolomide / Generic mfg., capecitabine / Generic mfg.
Enrollment change, Metastases: Capecitabine and Temozolomide for Neuroendocrine Cancers (clinicaltrials.gov) - Jun 30, 2013
P2, N=38, Active, not recruiting, Sponsor: Columbia University
Recruiting --> Completed N=29 --> 38
- Istodax (romidepsin) / Astellas, BMS
Trial termination, Metastases: Romidepsin in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors (clinicaltrials.gov) - Jun 2, 2013
P2, N=25, Terminated, Sponsor: National Cancer Institute (NCI)
N=29 --> 38 Active, not recruiting --> Terminated
- ||| Trial completion: Yttrium Y 90 SMT 487 in Treating Patients With Refractory or Recurrent Cancer (clinicaltrials.gov) - Apr 29, 2013
P1, N=60, Completed, Sponsor: Novartis Pharmaceuticals
Active, not recruiting --> Terminated Active, not recruiting --> Completed
- cixutumumab (IMC A12) / Eli Lilly
Enrollment closed, Metastases: Cixutumumab, Everolimus, and Octreotide Acetate in Treating Patients With Advanced Low to Intermediate Grade Neuroendocrine Carcinoma (clinicaltrials.gov) - Oct 23, 2012
P1, N=19, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- SIR-Spheres (yttrium-90 microspheres) / SIRTeX Medical
Trial termination: Internal Radiation Therapy in Treating Patients With Liver Metastases From Neuroendocrine Tumors (clinicaltrials.gov) - May 16, 2012
P2, N=10, Terminated, Sponsor: Vanderbilt-Ingram Cancer Center
Recruiting --> Active, not recruiting Active, not recruiting --> Terminated; due to slow accrual
- Farydak (panobinostat) / Secura Bio
Trial termination, Combination therapy: Panobinostat & Bortezomib in Pancreatic Cancer Progressing on Gemcitabine Therapy (clinicaltrials.gov) - Aug 24, 2011
P2, N=7, Terminated, Sponsor: Masonic Cancer Center, University of Minnesota
Active, not recruiting --> Terminated; due to slow accrual Active, not recruiting --> Terminated; Funding not available
- Farydak (panobinostat) / Secura Bio
Enrollment change, Combination therapy: Panobinostat & Bortezomib in Pancreatic Cancer Progressing on Gemcitabine Therapy (clinicaltrials.gov) - Aug 24, 2011
P2, N=7, Terminated, Sponsor: Masonic Cancer Center, University of Minnesota
Active, not recruiting --> Terminated; Funding not available N=65 --> 7